A Phase 2 interventional study of GZR101-80 and GZR33 or Insulin degludec/Insulin aspart or Insulin aspart30 (NovoRapid®30) in Type 2 Diabetes (T2DM), sponsored by Gan & Lee Pharmaceuticals.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-15.
Sponsored by Gan & Lee Pharmaceuticals. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Diabetes Mellitus, Type 2 by Gan & Lee Pharmaceuticals — 6 open to participants now, 9 under way, 1 of them phase 3. Diabetes Mellitus, Type 2 · Gan & Lee Pharmaceuticals.
Among the 17 studies in Diabetes Mellitus, Type 2 by Gan & Lee Pharmaceuticals, this one is the 4th largest by planned enrollment, is one of 2 that started in 2026, is one of 6 in phase 2, and was the 16th registered.
10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →6 of the 17 studies in Diabetes Mellitus, Type 2 by Gan & Lee Pharmaceuticals are open now, in 2 countries. Recruiting first, the newest first:
Gan & Lee Pharmaceuticals. · Sites in China
Ages 18+
Gan and Lee Pharmaceuticals, USA · Sites in Germany
Ages 18–70
Gan and Lee Pharmaceuticals, USA · Sites in China
Ages 18–75
Gan & Lee Pharmaceuticals. · Sites in China
Ages 18–60
Gan and Lee Pharmaceuticals, USA
Ages 18–50
By country, each count listing its studies:
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 7 · Phase 3 4
First in 2017; this study’s year is marked. 2 started in 2026.
This study's planned enrollment of 345 is above the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 92 across the 17 interventional studies. Of the 8 that completed or were terminated, 1 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Gan & Lee Pharmaceuticals., one of the names counted as Gan & Lee Pharmaceuticals. Under that name alone:
Gan & Lee Pharmaceuticals. is the lead sponsor of 30 studies on the registry; 15 are open to participants now.
1 of the studies in Diabetes Mellitus, Type 2 by Gan & Lee Pharmaceuticals that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07387003Gan & Lee Pharmaceuticals.Evaluate the Efficacy and Safety of GZR101-80 Injection in Patients With Type 2 Diabetes | 2027-02-11 |
Add it to your calendar (.ics) → With an account.
Among the 17 studies in Diabetes Mellitus, Type 2 by Gan & Lee Pharmaceuticals, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will be conducted to evaluate the efficacy and safety of GZR101-80 Injection in patients with type 2 diabetes mellitus inadequately controlled on oral antidiabetic drugs or Basal Insulin.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: GZR101-80
Drug: GZR33 or Insulin degludec/Insulin aspart or Insulin aspart30 (NovoRapid®30)
Administered SC
Administered SC
Change in Hemoglobin A1c (HbA1c) from baseline after 16 weeks of treatment.
Time frame: Baseline , 16 weeks
Change in fasting plasma glucose (FPG) from baseline after 16 weeks of treatment
Time frame: Baseline , 16 weeks
Safety Endpoints
Number of adverse events (AEs) and serious adverse events (SAEs), and number and percent
Time frame: Baseline , 17 weeks
Start is estimated for Apr 2026; primary completion for Feb 2027, 10 months later.
Of 194 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's planned 10 months is below that.
Counting every sponsor, half of 293 studies reached it within 15 months; a quarter within 11 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.